The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 2.15 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -2.50 — no flag raisedOK
- Earnings quality 94/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2026, as TERUMO CORPORATION reports it. History and quarterly detail are in the app.
- Cardiac and vascular company¥676.4B
- Blood and cell technologies company¥231.0B
- Medical care solutions company¥216.1B
- Terumo organ technologies¥8.0B
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about TERUMO CORPORATION, every answer cited to the official filings🔒
- The Intelligence Brief — added when TERUMO CORPORATION's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.